ascopubs.org

Gene-expression-profiling plus integrated multidisciplinary approach to detect new-generation risk-adapted prognostic index in smoldering myeloma and multiple myeloma (GIMPI).

The impact of glucagon-like peptide-1 agonists on MGUS progression in patients with type 2 diabetes. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...

BostonGene to Demonstrate Power of AI Models in Tumor and Immune Biology at the 2026 ASCO® Annual Meeting

Presentations highlight the clinical utility of AI-powered models and multimodal profiling for biomarker discovery, treatment response prediction, and patient stratification across diverse solid ...
ascopubs.org

Combined genomic profiling of cell-free DNA (cfDNA) and circulating tumor cell DNA (ctcDNA) in S1802, a prospective phase 3 trial for metastatic prostate cancer (mHSPC).

Androgen pathway gene expression and response to hormonal therapy in prostate cancer (SWOG S1216). This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include ...
Medscape

Use of Broad Genomic Profiling for Cancer Still Suboptimal

Broad genomic profiling was used in only 1 in 4 US patients with newly diagnosed metastatic cancer between 2020 and 2022, a new study reported. Although testing rates increased over this time period, ...

Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announced results from a systematic ...
Phys.org

Automated tool enables rapid, large-scale profiling of disease-linked RNA modifications

Researchers have developed a powerful tool capable of scanning thousands of biological samples to detect transfer ribonucleic acid (tRNA) modifications—tiny chemical changes to RNA molecules that help ...